Corrigendum to 'Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study': [ESMO Open Volume 6, Issue 4, August 2021, 100191].
作者信息
Hotta K, Saeki S, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Gemba K, Shiojiri M, Kato Y, Ninomiya T, Kubo T, Kishimoto J, Shioyama Y, Katsui K, Sasaki J, Kiura K, Sugio K
机构信息
Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama; Department of Respiratory Medicine, Okayama University Hospital, Okayama.
Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto.
出版信息
ESMO Open. 2022 Aug;7(4):100532. doi: 10.1016/j.esmoop.2022.100532. Epub 2022 Jul 6.
Abstract
摘要
相似文献
1
Corrigendum to 'Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study': [ESMO Open Volume 6, Issue 4, August 2021, 100191].《表皮生长因子受体（EGFR）突变的局部晚期非小细胞肺癌中吉非替尼诱导序贯放化疗：LOGIK0902/OLCSG0905 Ⅱ期研究》勘误：[《ESMO 开放》第 6 卷，第 4 期，2021 年 8 月，100191]
ESMO Open. 2022 Aug;7(4):100532. doi: 10.1016/j.esmoop.2022.100532. Epub 2022 Jul 6.
2
Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.吉非替尼诱导治疗后继以放化疗治疗表皮生长因子受体突变、局部晚期非小细胞肺癌：LOGIK0902/OLCSG0905 期研究。
ESMO Open. 2021 Aug;6(4):100191. doi: 10.1016/j.esmoop.2021.100191. Epub 2021 Jun 18.
3
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.吉非替尼联合标准放化疗治疗表皮生长因子受体（EGFR）突变的局部晚期非小细胞肺癌：LOGIK0902/OLCSG0905组间研究方案
Clin Lung Cancer. 2016 Jan;17(1):75-9. doi: 10.1016/j.cllc.2015.08.004. Epub 2015 Aug 18.
4
Corrigendum to 'Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study': [ESMO Open Volume 7, Issue 2, April 2022, 100466].《新辅助放化疗在手术治疗的Ⅲ期/N2期非小细胞肺癌中优于单纯化疗：一项回顾性单中心队列研究》勘误：[《ESMO Open》第7卷，第2期，2022年4月，100466]
ESMO Open. 2022 Jun;7(3):100523. doi: 10.1016/j.esmoop.2022.100523. Epub 2022 Jun 10.
5
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.表皮生长因子受体抑制在局部晚期非小细胞肺癌综合治疗中的应用
Semin Oncol. 2005 Apr;32(2 Suppl 3):S35-41. doi: 10.1053/j.seminoncol.2005.03.008.
6
Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial.放疗联合吉非替尼治疗不适合手术或同期放化疗的局部晚期非小细胞肺癌患者：一项 II 期临床试验。
Radiat Oncol. 2020 Jun 20;15(1):155. doi: 10.1186/s13014-020-01596-2.
7
Locally advanced cervical cancer - neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: A phase II study.局部晚期宫颈癌——新辅助化疗后序贯同步放化疗及靶向治疗作为维持治疗：一项II期研究。
J Cancer Res Ther. 2019 Oct-Dec;15(6):1359-1364. doi: 10.4103/jcrt.JCRT_39_18.
8
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).ACTIVE 研究方案：阿帕替尼或安慰剂联合吉非替尼作为表皮生长因子受体突变型晚期非小细胞肺癌（CTONG1706）患者的一线治疗。
Cancer Commun (Lond). 2019 Nov 7;39(1):69. doi: 10.1186/s40880-019-0414-4.
9
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.吉非替尼用于局部晚期或转移性非小细胞肺癌的一线治疗。
Health Technol Assess. 2010 Oct;14(Suppl. 2):71-9. doi: 10.3310/hta14suppl2/10.
10
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.特泊替尼联合吉非替尼治疗既往 EGFR 抑制剂治疗后出现 MET 过表达或扩增的 EGFR 突变型非小细胞肺癌患者：一项开放标签、Ib/II 期、多中心、随机试验（INSIGHT 研究）。
Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29.
Zotero 插件